Coya Therapeutics (COYA) Stock Forecast, Price Target & Predictions
COYA Stock Forecast
Coya Therapeutics stock forecast is as follows: an average price target of $18.00 (represents a 162.77% upside from COYA’s last price of $6.85) and a rating consensus of 'Buy', based on 3 wall street analysts offering a 1-year stock forecast.
COYA Price Target
The average price target for Coya Therapeutics (COYA) is $18.00 based on 1-year price targets from 3 Wall Street analysts in the past 3 months, with a price target range of $18.00 to $18.00. This represents a potential 162.77% upside from COYA's last price of $6.85.
COYA Analyst Ratings
According to 3 Wall Street analysts, Coya Therapeutics's rating consensus is 'Buy'. The analyst rating breakdown for COYA stock is 0 'Strong Buy' (0.00%), 3 'Buy' (100.00%), 0 'Hold' (0.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).
Coya Therapeutics Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Sep 16, 2024 | Raghuram Selvaraju | H.C. Wainwright | $18.00 | $6.12 | 194.12% | 162.77% |
The latest Coya Therapeutics stock forecast, released on Sep 16, 2024 by Raghuram Selvaraju from H.C. Wainwright, set a price target of $18.00, which represents a 194.12% increase from the stock price at the time of the forecast ($6.12), and a 162.77% increase from COYA last price ($6.85).
Coya Therapeutics Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | - | 1 | 1 |
| Avg Price Target | - | $18.00 | $18.00 |
| Last Closing Price | $6.85 | $6.85 | $6.85 |
| Upside/Downside | -100.00% | 162.77% | 162.77% |
In the current month, the average price target of Coya Therapeutics stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Coya Therapeutics's last price of $6.85. This month's average price target is down -100.00% compared to last quarter, and down -100.00% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Sep 16, 2024 | H.C. Wainwright | - | Buy | Initialise |
| Jun 12, 2024 | Rodman & Renshaw | - | Buy | Initialise |
| Jun 08, 2023 | Chardan Capital | Buy | Buy | Hold |
Coya Therapeutics's last stock rating was published by H.C. Wainwright on Sep 16, 2024. The company Initialise its COYA rating from "null" to "Buy".
Coya Therapeutics Financial Forecast
Coya Therapeutics Revenue Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Dec 23 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | $6.00M |
| Avg Forecast | $450.00K | $450.00K | $1.63M | $1.63M | $1.23M | $1.88M | $2.75M | $7.50M |
| High Forecast | $450.00K | $450.00K | $1.63M | $1.63M | $1.23M | $1.88M | $2.75M | $7.50M |
| Low Forecast | $450.00K | $450.00K | $1.63M | $1.63M | $1.23M | $1.88M | $2.75M | $7.50M |
| # Analysts | 1 | 1 | 1 | 1 | 1 | 2 | 1 | 1 |
| Surprise % | - | - | - | - | - | - | - | 0.80% |
Coya Therapeutics's average Quarter revenue forecast for Jun 24 based on 1 analysts is $2.75M, with a low forecast of $2.75M, and a high forecast of $2.75M. COYA's average Quarter revenue forecast represents a -54.18% decrease compared to the company's last Quarter revenue of $6.00M (Dec 23).
Coya Therapeutics EBITDA Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Dec 23 | |
|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 1 | 2 | 1 | 1 |
| EBITDA | - | - | - | - | - | - | - | $2.02M |
| Avg Forecast | $225.00K | $225.00K | $816.67K | $816.67K | $612.50K | $937.50K | $1.38M | $3.75M |
| High Forecast | $225.00K | $225.00K | $816.67K | $816.67K | $612.50K | $937.50K | $1.38M | $3.75M |
| Low Forecast | $225.00K | $225.00K | $816.67K | $816.67K | $612.50K | $937.50K | $1.38M | $3.75M |
| Surprise % | - | - | - | - | - | - | - | 0.54% |
1 analysts predict COYA's average Quarter EBITDA for Jun 24 to be $1.38M, with a high of $1.38M and a low of $1.38M. This is -31.77% lower than Coya Therapeutics's previous annual EBITDA (Dec 23) of $2.02M.
Coya Therapeutics Net Income Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Dec 23 | |
|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 1 | 2 | 1 | 1 |
| Net Income | - | - | - | - | - | - | - | $1.27M |
| Avg Forecast | $-6.82M | $-6.82M | $-3.45M | $-5.42M | $-5.40M | $-5.40M | $-2.54M | $3.84M |
| High Forecast | $-6.82M | $-6.82M | $-3.45M | $-5.42M | $-5.40M | $-5.40M | $-2.54M | $3.84M |
| Low Forecast | $-6.82M | $-6.82M | $-3.45M | $-5.42M | $-5.40M | $-5.40M | $-2.54M | $3.84M |
| Surprise % | - | - | - | - | - | - | - | 0.33% |
Coya Therapeutics's average Quarter net income forecast for Jun 24 is $-2.54M, with a range of $-2.54M to $-2.54M. COYA's average Quarter net income forecast represents a -300.29% decrease compared to the company's last Quarter net income of $1.27M (Dec 23).
Coya Therapeutics SG&A Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Dec 23 | |
|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 1 | 2 | 1 | 1 |
| SG&A | - | - | - | - | - | - | - | $2.38M |
| Avg Forecast | $484.32K | $484.32K | $1.76M | $1.76M | $1.32M | $2.02M | $2.96M | $8.07M |
| High Forecast | $484.32K | $484.32K | $1.76M | $1.76M | $1.32M | $2.02M | $2.96M | $8.07M |
| Low Forecast | $484.32K | $484.32K | $1.76M | $1.76M | $1.32M | $2.02M | $2.96M | $8.07M |
| Surprise % | - | - | - | - | - | - | - | 0.29% |
Coya Therapeutics's average Quarter SG&A projection for Jun 24 is $2.96M, based on 1 Wall Street analysts, with a range of $2.96M to $2.96M. The forecast indicates a 24.50% rise compared to COYA last annual SG&A of $2.38M (Dec 23).
Coya Therapeutics EPS Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Dec 23 | |
|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 1 | 2 | 1 | 1 |
| EPS | - | - | - | - | - | - | - | $0.09 |
| Avg Forecast | $-0.46 | $-0.46 | $-0.23 | $-0.36 | $-0.36 | $-0.36 | $-0.17 | $0.26 |
| High Forecast | $-0.46 | $-0.46 | $-0.23 | $-0.36 | $-0.36 | $-0.36 | $-0.17 | $0.26 |
| Low Forecast | $-0.46 | $-0.46 | $-0.23 | $-0.36 | $-0.36 | $-0.36 | $-0.17 | $0.26 |
| Surprise % | - | - | - | - | - | - | - | 0.34% |
According to 1 Wall Street analysts, Coya Therapeutics's projected average Quarter EPS for Jun 24 is $-0.17, with a low estimate of $-0.17 and a high estimate of $-0.17. This represents a -293.40% decrease compared to COYA previous annual EPS of $0.09 (Dec 23).
Coya Therapeutics Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| INAB | IN8bio | $0.30 | $14.00 | 4566.67% | Buy |
| HLVX | HilleVax | $1.90 | $32.00 | 1584.21% | Hold |
| LIFE | aTyr Pharma | $1.90 | $11.00 | 478.95% | Buy |
| DRMA | Dermata Therapeutics | $1.22 | $6.00 | 391.80% | Buy |
| FENC | Fennec Pharmaceuticals | $4.65 | $15.75 | 238.71% | Buy |
| GANX | Gain Therapeutics | $2.07 | $7.00 | 238.16% | Buy |
| CUE | Cue Biopharma | $1.49 | $5.00 | 235.57% | Buy |
| OPT | Opthea | $4.21 | $14.00 | 232.54% | Buy |
| INZY | Inozyme Pharma | $4.42 | $14.67 | 231.90% | Buy |
| STRO | Sutro Biopharma | $3.69 | $11.14 | 201.90% | Buy |
| COYA | Coya Therapeutics | $6.85 | $18.00 | 162.77% | Buy |
| DAWN | Day One Biopharmaceuticals | $14.81 | $38.80 | 161.99% | Buy |
| ELYM | Eliem Therapeutics | $5.11 | $13.00 | 154.40% | Buy |
| ABOS | Acumen Pharmaceuticals | $2.95 | $7.00 | 137.29% | Buy |
| TCRX | TScan Therapeutics | $5.08 | $12.00 | 136.22% | Buy |
| TERN | Terns Pharmaceuticals | $7.10 | $14.25 | 100.70% | Buy |
| CNTA | Centessa Pharmaceuticals | $15.89 | $21.67 | 36.38% | Buy |
COYA Forecast FAQ
Is Coya Therapeutics a good buy?
Yes, according to 3 Wall Street analysts, Coya Therapeutics (COYA) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 3 'Buy' recommendations, accounting for 100.00% of COYA's total ratings.
What is COYA's price target?
Coya Therapeutics (COYA) average price target is $18 with a range of $18 to $18, implying a 162.77% from its last price of $6.85. The data is based on 3 Wall Street analysts who provided a twelve-month price target estimate in the last three months.
Will Coya Therapeutics stock go up soon?
According to Wall Street analysts' prediction for COYA stock, the company can go up by 162.77% (from the last price of $6.85 to the average price target of $18), up by 162.77% based on the highest stock price target, and up by 162.77% based on the lowest stock price target.
Can Coya Therapeutics stock reach $10?
COYA's average twelve months analyst stock price target of $18 supports the claim that Coya Therapeutics can reach $10 in the near future.
What are Coya Therapeutics's analysts' financial forecasts?
Coya Therapeutics's analysts financial forecasts for the fiscal year (Dec 2024) are as follows: average revenue is $5.85M (high $5.85M, low $5.85M), average EBITDA is $2.92M (high $2.92M, low $2.92M), average net income is $-13.341M (high $-13.341M, low $-13.341M), average SG&A $6.3M (high $6.3M, low $6.3M), and average EPS is $-0.894 (high $-0.894, low $-0.894). COYA's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $4.17M (high $4.17M, low $4.17M), average EBITDA is $2.08M (high $2.08M, low $2.08M), average net income is $-22.509M (high $-22.509M, low $-22.509M), average SG&A $4.48M (high $4.48M, low $4.48M), and average EPS is $-1.509 (high $-1.509, low $-1.509).
Did the COYA's actual financial results beat the analysts' financial forecasts?
Based on Coya Therapeutics's last annual report (Dec 2023), the company's revenue was $6M, which missed the average analysts forecast of $7.5M by -19.97%. Apple's EBITDA was $-7.903M, missing the average prediction of $3.75M by -310.76%. The company's net income was $-7.988M, missing the average estimation of $3.84M by -308.14%. Apple's SG&A was $7.83M, missing the average forecast of $8.07M by -2.96%. Lastly, the company's EPS was $-0.79, missing the average prediction of $0.257 by -407.03%. In terms of the last quarterly report (Dec 2023), Coya Therapeutics's revenue was $6M, missing the average analysts' forecast of $7.5M by -19.97%. The company's EBITDA was $2.02M, missing the average prediction of $3.75M by -46.26%. Coya Therapeutics's net income was $1.27M, missing the average estimation of $3.84M by -67.01%. The company's SG&A was $2.38M, missing the average forecast of $8.07M by -70.55%. Lastly, the company's EPS was $0.0879, missing the average prediction of $0.257 by -65.84%